Intranasal treatment of neurodegenerative diseases and stroke

Frontiers in Bioscience - Scholar

Volumn 4 S, Issue 1, 2012, Pages 74-89

  Gomez, Diana ^a   Martinez, Jose A ^a   Hanson, Leah R ^b   Frey II, William H ^b   Toth, Cory C ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b REGIONS HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Dementia; Diabetes; Intranasal; Neurodegenerative; Review; Stroke

Indexed keywords

CLONAZEPAM; DONEPEZIL; GALANTAMINE; INSULIN; NIMODIPINE; OXYTOCIN; PLACEBO; QUILOSTIGMINE; RIFAMPICIN; RISPERIDONE; RIVASTIGMINE; SUMATRIPTAN; DRUG;

ALZHEIMER DISEASE; ARTICLE; ASTHENIA; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; CEREBROVASCULAR ACCIDENT; DEGENERATIVE DISEASE; DEMENTIA; DIABETES MELLITUS; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LYMPH VESSEL; NAUSEA; NONHUMAN; OLFACTORY NERVE; SINGLE DRUG DOSE; TRIGEMINAL NERVE; VOMITING; ANIMAL; INTRANASAL DRUG ADMINISTRATION; METABOLISM; REVIEW;

ADMINISTRATION, INTRANASAL; ANIMALS; BLOOD-BRAIN BARRIER; HUMANS; NEURODEGENERATIVE DISEASES; PHARMACEUTICAL PREPARATIONS; STROKE;

EID: 84862286848     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/252     Document Type: Article

References (170)

1. W. Pardridge, W. Oldendorf, P Cancilla, HJ Frank: Blood brain barrier: interface between internal medicine and the brain. Annals of Internal Medicine 105, 82-95 (1986) (Pubitemid 16097930)
2. WA Banks: Delivery of peptides to the brain: emphasis on therapeutic development. Biopolymers 90, 589-594 (2008)
3. M Suzumura. M Kawamura, S Kikuchi. A Kawada, Y Shibayama, J Otabe: Intranasal oxytocin for the induction and stimulation of labor. J Jpn Obstet Gynecol Soc 13, 42-50 (1966)
4. C Jones: Clinical experience with intranasal oxytocin spray. Med J Aust 2, 1099-1101 (1966)
5. RT Hoover: Intranasal oxytocin in eighteen hundred patients. A study on its safety as used in a community hospital. Am J Obstet Gynecol 110, 788-794 (1971)
6. S Sjostedt: Induction of labour. A comparison of intranasal and transbuccal administration of oxytocin. Acta Obstet Gynecol Scand Suppl 7, Suppl 7:1-17 (1969)
7. J Laine: Experience of the use of intranasal, buccal and intravenous oxytocin as methods of inducing labour. Acta Obstet Gynecol Scand 49, 149-159 (1970)
8. WHn Frey, inventor Chiron Corporation, assignee. Method of administering neurologic agents to the brain. US. 1997.
9. Wn Frey, inventor Neurologic Agents for Nasal Administration to the Brain Geneva, Switzerland. 1991 (priority date 5.12.89).
10. S. Dhuria, L. Hanson, W. Frey, 2nd: Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 99, 1654-1673 (2010)
11. WHn Frey: Bypassing the blood-brain barrier to deliver therapeutic agents to the brain and spinal cord. Drug Del Tech 2, 46-49 (2002)
12. R. Thorne, G. Pronk, V Padmanabhan, WHn Frey: Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127, 481-496 (2004) (Pubitemid 38950662)
13. D. Dhanda, WH. Frey, D Leopold, UB Kompella: Approaches for drug deposition in the human olfactory epithelium. Drug Del Tech 5, 64-72 (2005)
14. LB Buck. The chemical senses. In: Principles of neural science. Eds: Kandel ER, Schwartz JH, Jessell TM, eds. pp. 625-652 McGraw-Hill Companies, New York: (2000)
15. S. Fuss, M Omura, P Mombaerts: The Grueneberg ganglion of the mouse projects axons to glomeruli in the olfactory bulb. Eur J Neurosci 22, 2649-2654 (2005) (Pubitemid 41759007)
16. D. Koos, SE Fraser: The Grueneberg ganglion projects to the olfactory bulb. Neuroreport 16, 1929-1932 (2005) (Pubitemid 41653516)
17. B. Balin, R. Broadwell, M Salcman, M el-Kalliny: Avenues for entry of peripherally administered protein to the central nervous system in mouse, rat, and squirrel monkey. J Comp Neurol 251, 260-280 (1986) (Pubitemid 16027854)
18. B Jansson, E Bjork: Visualization of in vivo olfactory uptake and transfer using fluorescein dextran. J Drug Target. 10, 379-386 (2002)
19. R. Thorne, L. Hanson, T. Ross, D Tung. WH Frey, 2nd: Delivery of interferon-beta to the monkey nervous system following intranasal administration. Neuroscience 152, 785-797 (2008)
20. T. Ross, R. Zuckermann, C Reinhard. WH Frey, 2nd: Intranasal administration delivers peptoids to the rat central nervous system. Neurosci Lett 439, 30-33 (2008)
21. N Nonaka. SA Farr, H Kageyama. S Shioda, WA Banks: Delivery of galanin-like peptide to the brain: targeting with intranasal delivery and cyclodextrins. J Pharmacol Exp Ther 325, 513-519 (2008) (Pubitemid 351574811)
22. A Mackay-Sim. Neurogenesis in the adult olfactory neuroepithelium. In: Handbook of olfaction and gustation. Eds: Doty RL, ed. 93-113. Marcel Dekker, Inc., New York: (2003)
23. S. Williams, R. Franklin, SC Barnett: Response of olfactory ensheathing cells to the degeneration and regeneration of the peripheral olfactory system and the involvement of the neuregulins. J Comp Neurol 470, 50-62 (2004) (Pubitemid 38160697)
24. R. Thorne, G. Pronk, V Padmanabhan, WH Frey: Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127, 481-496 (2004) (Pubitemid 38950662)
25. R. Thorne, W. Frey, 2nd: Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations. Clin Pharmacokinet 40, 907-946 (2001) (Pubitemid 34066688)
26. H Baker, RF Spencer: Transneuronal transport of peroxidase-conjugated wheat germ agglutinin (WGA-HRP) from the olfactory epithelium to the brain of the adult rat. Exp Brain Res 63, 461-473 (1986) (Pubitemid 16036221)
27. R. Broadwell, BJ Balin: Endocytic and exocytic pathways of the neuronal secretory process and transsynaptic transfer of wheat germ agglutinin- horseradish peroxidase in vivo. J Comp Neurol 242, 632-650 (1985) (Pubitemid 16176081)
28. K Kristensson, Y Olsson: Uptake of exogenous proteins in mouse olfactory cells. Acta Neuropathol 19, 145-154 (1971)
29. X. Chen, J. Fawcett, Y. Rahman, T. Ala, WH Frey Ii: Delivery of Nerve Growth Factor to the Brain via the Olfactory Pathway. J. Alzheimers. Dis. 1, 35-44 (1998)
30. H. Zhao, X. Liu, X. Mao, CF Chen: Intranasal delivery of nerve growth factor to protect the central nervous system against acute cerebral infarction. Chin Med Sci J 19, 257-261 (2004) (Pubitemid 40128007)
31. D. Clerico, W. To, DC Lanza. Anatomy of the human nasal passages. In: Handbook of olfaction and gustation. Eds: Doty RL, ed. 1-16. Marcel Dekker, Inc., New York (2003)
32. H Gray. Gray's anatomy., 15th revised (Classic Collectors edition) ed. New York: Bounty Books, 1978
33. M. Schaefer, B Bottger. WL Silver, TE Finger: Trigeminal collaterals in the nasal epithelium and olfactory bulb: a potential route for direct modulation of olfactory information by trigeminal stimuli. J Comp Neurol 444, 221-226 (2002) (Pubitemid 34117087)
34. T. Ross, P. Martinez, J. Renner, R. Thorne, L. Hanson, WH Frey: Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. Journal of Neuroimmunology 151, 66-77 (2004) (Pubitemid 38624401)
35. S. Dhuria, L. Hanson, W. Frey, 2nd: Novel vasoconstrictor formulation to enhance intranasal targeting of neuropeptide therapeutics to the central nervous system. J Pharmacol Exp Ther 328, 312-320 (2009)
36. L. Hanson, P. Martinez, S Taheri. L Kamsheh, E Mignot, WHI Frey: Intranasal administration of hypocretin 1 (orexin A) bypasses the blood-brain barrier & targets the brain: A new strategy for the treatment of narcolepsy. Drug Del Tech 4, 66-70 (2004)
37. N Cauna. Blood and nerve supply of the nasal lining. In: The nose: Upper airway physiology and the atmospheric environment. Eds: Proctor DF, Andersen I, eds. 45-69 Elsevier Biomedical Press, Amsterdam (1982)
38. G Grevers, U Herrmann: Fenestrated endothelia in vessels of the nasal mucosa. An electron-microscopic study in the rabbit. Arch Otorhinolaryngol 244, 55-60 (1987) (Pubitemid 17083392)
39. P Va. Diest, MW Kanan: An ultrastructural study of the endonasal microcirculation in the Wistar rat during fetal and early postnatal life. J Anat 128, 293-300 (1979) (Pubitemid 9118352)
40. H. Cserr, D. Cooper, P. Suri, CS Patlak: Efflux of radiolabeled polyethylene glycols and albumin from rat brain. Am J Physiol 240, F319-328 (1981)
41. D. Groothuis, M. Vavra, K. Schlageter, E. Kang, A. Itskovich, S Hertzler. CV Allen, HL Lipton: Efflux of drugs and solutes from brain: the interactive roles of diffusional transcapillary transport, bulk flow and capillary transporters. J Cereb Blood Flow Metab 27, 43-56 (2007) (Pubitemid 46006583)
42. P Hadaczek. Y Yamashita, H Mirek. L Tamas, M. Bohn, C Noble. JW Park, K Bankiewicz: The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain. Mol Ther 14, 69-78 (2006) (Pubitemid 43922142)
43. M. Rennels, O. Blaumanis, PA Grady: Rapid solute transport throughout the brain via paravascular fluid pathways. Adv Neurol 52, 431-439 (1990)
44. M. Rennels, T. Gregory, O. Blaumanis, K Fujimoto, PA Grady: Evidence for a 'paravascular' fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space. Brain Res 326, 47-63 (1985) (Pubitemid 15160009)
45. M. Bradbury, RJ Westrop: Factors influencing exit of substances from cerebrospinal fluid into deep cervical lymph of the rabbit. J Physiol 339, 519-534 (1983) (Pubitemid 13104105)
46. E Hatterer. N Davoust, M Didier-Bazes. C Vuaillat, C Malcus. MF Belin, S Nataf: How to drain without lymphatics? Dendritic cells migrate from the cerebrospinal fluid to the B-cell follicles of cervical lymph nodes. Blood 107, 806-812 (2006) (Pubitemid 43076409)
47. M Johnston. A Zakharov, C Papaiconomou. G Salmasi, D Armstrong: Evidence of connections between cerebrospinal fluid and nasal lymphatic vessels in humans, non-human primates and other mammalian species. Cerebrospinal Fluid Res 1, 2 (2004)
48. S Kida. A Pantazis, RO Weller: CSF drains directly from the subarachnoid space into nasal lymphatics in the rat. Anatomy, histology and immunological significance. Neuropathol Appl Neurobiol 19, 480-488 (1993) (Pubitemid 24010674)
49. B. Walter, V. Valera, S Takahashi, T Ushiki: The olfactory route for cerebrospinal fluid drainage into the peripheral lymphatic system. Neuropathol Appl Neurobiol 32, 388-396 (2006) (Pubitemid 44015580)
50. J Born. T Lange, W Kern. GP McGregor, U Bickel, HL Fehm: Sniffing neuropeptides: a transnasal approach to the human brain. Nature Neuroscience 5, 514-516 (2002) (Pubitemid 34568991)
51. G. Francis, J. Martinez, W. Liu, K Xu. A Ayer, J Fine. UI Tuor, G Glazner. LR Hanson, W. Frey, 2nd, C Toth: Intranasal insulin prevents cognitive decline, cerebral atrophy and white matter changes in murine type I diabetic encephalopathy. Brain 131, 3311-3334 (2008)
52. G Francis. J Martinez, W Liu. T Nguyen, A Ayer. J Fine, D Zochodne. LR Hanson, W. Frey, 2nd, C Toth: Intranasal Insulin Ameliorates Experimental Diabetic Neuropathy. Diabetes 58, 934-945 (2009)
53. S. Dhuria, L. Hanson, W. Frey, 2nd: Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system. J Pharm Sci 98, 2501-2515 (2009)
54. L Illum: Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 56, 3-17 (2004) (Pubitemid 38195323)
55. K. Kandimalla, MD Donovan: Localization and differential activity of P-glycoprotein in the bovine olfactory and nasal respiratory mucosae. Pharm Res 22, 1121-1128 (2005) (Pubitemid 41127070)
56. C. Graff, GM Pollack: Functional evidence for Pglycoprotein at the nose-brain barrier. Pharm Res 22, 86-93 (2005) (Pubitemid 40558150)
57. M. Wioland, J Fleury-Feith. P Corlieu, F Commo. G Monceaux, J Lacau-St-Guily, JF Bernaudin: CFTR, MDR1, and MRP1 immunolocalization in normal human nasal respiratory mucosa. J Histochem Cytochem 48, 1215-1222 (2000)
58. K. Kandimalla, MD Donovan: Carrier mediated transport of chlorpheniramine and chlorcyclizine across bovine olfactory mucosa: implications on nose-to-brain transport. J Pharm Sci 94, 613-624 (2005) (Pubitemid 40476525)
59. C. Graff, GM Pollack: P-Glycoprotein attenuates brain uptake of substrates after nasal instillation. Pharm Res 20, 1225-1230 (2003) (Pubitemid 36951847)
60. A Minn. S Leclerc, J. Heydel, A. Minn, C Denizcot. M Cattarelli, P Netter, D Gradinaru: Drug transport into the mammalian brain: the nasal pathway and its specific metabolic barrier. J Drug Target 10, 285-296 (2002) (Pubitemid 34746310)
61. MA Sarkar: Drug metabolism in the nasal mucosa. Pharm Res 9, 1-9 (1992)
62. F Miragall. D Krause, U d. Vries, R Dermietzel: Expression of the tight junction protein ZO-1 in the olfactory system: presence of ZO-1 on olfactory sensory neurons and glial cells. J Comp Neurol 341, 433-448 (1994) (Pubitemid 24072838)
63. T. Vyas, A. Babbar, R. Sharma, S Singh, A Misra: Intranasal mucoadhesive microemulsions of clonazepam: preliminary studies on brain targeting. J Pharm Sci 95, 570-580 (2006)
64. T. Vyas, A. Babbar, R. Sharma, S Singh, A Misra: Preliminary brain-targeting studies on intranasal mucoadhesive microemulsions of sumatriptan. AAPS Pharm Sci Tech 7, E8 (2006)
65. M Kumar. A Misra, A. Babbar, A. Mishra, P Mishra, K Pathak: Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm 358, 285-291 (2008)
66. Q Zhang. X Jiang, W Jiang. W Lu, L Su, Z Shi: Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int J Pharm 275, 85-96 (2004) (Pubitemid 38481522)
67. Q. Zhang, L. Zha, Y Zhang. WM Jiang, W Lu. ZQ Shi, X. Jiang, SK Fu: The brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in rats. J Drug Target 14, 281-290 (2006) (Pubitemid 44173294)
68. X Wang. N Chi, X Tang: Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting. Eur J Pharm Biopharm 70, 735-740 (2008)
69. X Wang. H He, W Leng, X Tang: Evaluation of brain-targeting for the nasal delivery of estradiol by the microdialysis method. Int J Pharm 317, 40-46 (2006) (Pubitemid 43866343)
70. S. Chen, K Eiting. K Cui, A. Leonard, D Morris. CY Li, K Farber. AP Sileno, M. Houston, Jr., P. Johnson, S. Quay, HR Costantino: Therapeutic utility of a novel tight junction modulating peptide for enhancing intranasal drug delivery. J Pharm Sci 95, 1364-1371 (2006) (Pubitemid 43874450)
71. S. Davis, L Illum: Absorption enhancers for nasal drug delivery. Clin Pharmacokinet 42, 1107-1128 (2003) (Pubitemid 37357648)
72. C Dufes. JC Olivier, F Gaillard. A Gaillard, W Couet, JM Muller: Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats. Int J Pharm 255, 87-97 (2003) (Pubitemid 36369593)
73. T Sakane. M Akizuki, S Yamashita. H Sezaki, T Nadai: Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the dissociation of the drug. J Pharm Pharmacol 46, 378-379 (1994) (Pubitemid 24140941)
74. S. Charlton, J Whetstone. ST Fayinka, K. Read, L Illum, SS Davis: Evaluation of direct transport pathways of glycine receptor antagonists and an angiotensin antagonist from the nasal cavity to the central nervous system in the rat model. Pharm Res 25, 1531-1543 (2008)
75. V. Jogani, P. Shah, P Mishra. AK Mishra, AR Misra: Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting. Alzheimer Dis Assoc Disord 22, 116-124 (2008)
76. S. Charlton, S. Davis, L Illum: Evaluation of effect of ephedrine on the transport of drugs from the nasal cavity to the systemic circulation and the central nervous system. J Drug Target 15, 370-377 (2007) (Pubitemid 46887868)
77. N. Barakat, S. Omar, AA Ahmed: Carbamazepine uptake into rat brain following intra-olfactory transport. J Pharm Pharmacol 58, 63-72 (2006) (Pubitemid 43041997)
78. Z Cai. SX Hou, Z. Yang, X. Song, Q. Chen, Y. Li, BB Zhao: [Brain targeting of gastrodin nasal in situ gel]. Sichuan Da Xue Xue Bao Yi Xue Ban 39, 438-440 (2008)
79. Y Zhao. P Yue, T Tao, QH Chen: Drug brain distribution following intranasal administration of Huperzine A in situ gel in rats. Acta Pharmacol Sin 28, 273-278 (2007) (Pubitemid 46155546)
80. X Gao. B Wu, Q Zhang. J Chen, J Zhu. W Zhang, Z Rong. H Chen, X Jiang: Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. J Control Release 121, 156-167 (2007) (Pubitemid 47212537)
81. B. Plassman, K. Langa, G. Fisher, S. Heeringa, D. Weir, M. Ofstedal, J. Burke, M. Hurd, G. Potter, W. Rodgers, D. Steffens, R. Willis, RB Wallace: Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology 29, 125-132 (2007) (Pubitemid 350191430)
82. J Hardy, DJ Selkoe: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356 (2002) (Pubitemid 34790756)
83. T. Dickson, H. Saunders, JC Vickers: Relationship between apolipoprotein E and the amyloid deposits and dystrophic neurites of Alzheimer's disease. Neuropathol Appl Neurobiol 23, 483-491 (1997) (Pubitemid 28019850)
84. GL Wenk: Neuropathologic changes in Alzheimer's disease. J Clin Psychiatry 64 Suppl 9, 7-10 (2003) (Pubitemid 37040372)
85. R Brookmeyer. E Johnson, K Ziegler-Graham, HM Arrighi: Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3, 186-191 (2007) (Pubitemid 46825511)
86. A Ott. MM Breteler, F va. Harskamp, J. Claus, T. van der Cammen, D. Grobbee, A Hofman: Prevalence of Alzheimer's disease and vascular dementia: association with education. The Rotterdam study. BMJ 310, 970-973 (1995)
87. R. Caselli, T. Beach, R Yaari, EM Reiman: Alzheimer's disease a century later. J Clin Psychiatry 67, 1784-1800 (2006) (Pubitemid 44955162)
88. S Gauthier. OL Lopez, G Waldemar. RW Jones, J Cummings. R Zhang, R Schindler, E Schwam: Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease. Int Psychogeriatr 22, 973-983 (2010)
89. B Borah. P Sacco, V Zarotsky: Predictors of adherence among Alzheimer's disease patients receiving oral therapy. Curr Med Res Opin 26, 1957-1965
90. A Pariente. DJ Sanctussy, G Miremont-Salame. N Moore, F Haramburu, A Fourrier-Reglat: Factors associated with serious adverse reactions to cholinesterase inhibitors: a study of spontaneous reporting. CNS Drugs 24, 55-63 (2010)
91. Y Okura, Y Matsumoto: DNA vaccine therapy for Alzheimer's disease: present status and future direction. Rejuvenation Res 11, 301-308 (2008) (Pubitemid 351601163)
92. H. Kim, K Tahara. JA Maxwell, R Lalonde. T Fukuiwa, K Fujihashi. KR Van Kampen, F. Kong, D. Tang, K Fukuchi: Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease. J Gene Med 9, 88-98 (2007) (Pubitemid 46444486)
93. H. Kim, J. Jin, J. Maxwell, K Fukuchi: Enhancing Th2 immune responses against amyloid protein by a DNA primeadenovirus boost regimen for Alzheimer's disease. Immunol Lett 112, 30-38 (2007) (Pubitemid 47331686)
94. M Maier. TJ Seabrook, N. Lazo, L Jiang. P Das, C Janus, CA Lemere: Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. J Neurosci 26, 4717-4728 (2006) (Pubitemid 44315311)
95. J. Rinne, D. Brooks, M. Rossor, N. Fox, R Bullock. WE Klunk, C. Mathis, K Blennow. J Barakos, A. Okello, S Rodrigue. Martinez de Liano, E Liu. M Koller, K. Gregg, D Schenk. R Black, M Grundman: 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9, 363-372 (2010)
96. R D. Rosa, A. Garcia, C Braschi. S Capsoni, L Maffei. N Berardi, A Cattaneo: Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci U S A 102, 3811-3816 (2005) (Pubitemid 40360709)
97. S Capsoni. S Giannotta, A Cattaneo: Nerve growth factor and galantamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci U S A 99, 12432-12437 (2002)
98. S Covaceuszach. S Capsoni, G Ugolini. F Spirito, D Vignone, A Cattaneo: Development of a non invasive NGFbased therapy for Alzheimer's disease. Curr Alzheimer Res 6, 158-170 (2009)
99. S Capsoni. S Covaceuszach, G Ugolini. F Spirito, D Vignone. B Stefanini, G Amato, A Cattaneo: Delivery of NGF to the brain: intranasal versus ocular administration in anti-NGF transgenic mice. J Alzheimers Dis 16, 371-388 (2009)
100. C. Lemere, R Maron. DJ Selkoe, HL Weiner: Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol 20, 705-711 (2001) (Pubitemid 34072837)
101. H. Weiner, C. Lemere, R Maron. ET Spooner, T. Grenfell, C Mori. S Issazadeh, W. Hancock, DJ Selkoe: Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol 48, 567-579 (2000)
102. D Frenkel. R Maron, D. Burt, HL Weiner: Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. J Clin Invest 115, 2423-2433 (2005) (Pubitemid 41266204)
103. Y Matsuoka. AJ Gray, C Hirata-Fukae. SS Minami, E. Waterhouse, M. Mattson, F. La Ferla, I Gozes, PS Aisen: Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci 31, 165-170 (2007) (Pubitemid 46742300)
104. I Gozes, I Divinski: NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell. Curr Alzheimer Res 4, 507-509 (2007) (Pubitemid 350248382)
105. C. Ballard, N. Greig, A. Guillozet-Bongaarts, A Enz, S Darvesh: Cholinesterases: roles in the brain during health and disease. Curr Alzheimer Res 2, 307-318 (2005) (Pubitemid 40980189)
106. M Yamada. T Chiba, J Sasabe. K Terashita, S Aiso, M Matsuoka: Nasal Colivelin treatment ameliorates memory impairment related to Alzheimer's disease. Neuropsychopharmacology 33, 2020-2032 (2008) (Pubitemid 351832605)
107. H. Costantino, A. Leonard, G Brandt. PH Johnson, SC Quay: Intranasal administration of acetylcholinesterase inhibitors. BMC Neurosci 9 Suppl 3, S6 (2008)
108. M Dahlin, E Bjork: Nasal administration of a physostigmine analogue (NXX-066) for Alzheimer's disease to rats. Int J Pharm 212, 267-274 (2001) (Pubitemid 32119452)
109. J. Sramek, J Hourani. SS Jhee, NR Cutler: NXX-066 in patients with Alzheimer's disease: a bridging study. Life Sci 64, 1215-1221 (1999) (Pubitemid 29156869)
110. D. Owens, B Zinman, G Bolli: Alternative routes of insulin delivery. Diabetic Medicine 20, 886-898 (2003) (Pubitemid 41701487)
111. WH. Frey, inventor Method for administering insulin to the brain. US Patent: Chiron Corporation. 2001.
112. E Steen. BM Terry, E. Rivera, J. Cannon, T. Neely, R Tavares. XJ Xu, J. Wands, SM de la Monte: Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 7, 63-80 (2005) (Pubitemid 40387185)
113. S Craft, GS Watson: Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3, 169-178 (2004) (Pubitemid 38229951)
114. L Frolich. D Blum-Degen, P Riederer, S Hoyer: A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Annals of the New York Academy of Sciences 893, 290-293 (1999) (Pubitemid 30038089)
115. C. Jolivalt, C. Lee, K. Beiswenger, J. Smith, M Orlov. MA Torrance, E Masliah: Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J Neurosci Res 86, 3265-3274 (2008)
116. E. Korf, L. White, P Scheltens, LJ Launer: Brain aging in very old men with type 2 diabetes: the Honolulu-Asia Aging Study. Diabetes Care 29, 2268-2274 (2006) (Pubitemid 44899864)
117. J. Luchsinger, M. Tang, S Shea, R Mayeux: Hyperinsulinemia and risk of Alzheimer disease. Neurology 63, 1187-1192 (2004) (Pubitemid 39350015)
118. T. Nelson, M. Sun, J Hongpaisan, DL Alkon: Insulin, PKC signaling pathways and synaptic remodeling during memory storage and neuronal repair. Eur J Pharmacol 585, 76-87 (2008)
119. H Pilcher: Alzheimer's disease could be "type 3 diabetes". Lancet Neurol 5, 388-389 (2006)
120. L Zhao. B Teter, T Morihara. GP Lim, S. Ambegaokar, O. Ubeda, S. Frautschy, GM Cole: Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. Journal of Neuroscience 24, 11120-11126 (2004) (Pubitemid 40012971)
121. C Benedict. M Hallschmid, A Hatke. B Schultes, H. Fehm, J Born, W Kern: Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29, 1326-1334 (2004) (Pubitemid 39024358)
122. C Benedict. M Hallschmid, K Schmitz. B Schultes, F Ratter. HL Fehm, J Born, W Kern: Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology 32, 239-243 (2007) (Pubitemid 44967803)
123. M. Reger, G. Watson, W. Frey, L. Baker, B Cholerton. ML Keeling, D. Belongia, M. Fishel, S. Plymate, G. Schellenberg, M. Cherrier, S Craft: Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol. Aging 27, 451-458 (2006) (Pubitemid 43185331)
124. M. Reger, G. Watson, P. Green, C. Wilkinson, L. Baker, B Cholerton. MA Fishel, S. Plymate, J. Breitner, W De Groodt. P Mehta, S Craft: Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70, 440-448 (2008)
125. Y Deng. B Li, Y Liu. K Iqbal, I Grundke-Iqbal, CX Gong: Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease. Am J Pathol 175, 2089-2098 (2009)
126. T Baumgartner. M Heinrichs, A Vonlanthen. U Fischbacher, E Fehr: Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. Neuron 58, 639-650 (2008) (Pubitemid 351672358)
127. M Kosfeld. M Heinrichs, P. Zak, U Fischbacher, E Fehr: Oxytocin increases trust in humans. Nature 435, 673-676 (2005) (Pubitemid 40825511)
128. P Kirsch. C Esslinger, Q Chen. D Mier, S Lis. S Siddhanti, H Gruppe. VS Mattay, B Gallhofer, A Meyer-Lindenberg: Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci 25, 11489-11493 (2005) (Pubitemid 43083720)
129. K. Parker, C. Buckmaster, A. Schatzberg, DM Lyons: Intranasal oxytocin administration attenuates the ACTH stress response in monkeys. Psychoneuroendocrinology 30, 924-929 (2005) (Pubitemid 40977915)
130. U Rimmele. K Hediger, M Heinrichs, P Klaver: Oxytocin makes a face in memory familiar. J Neurosci 29, 38-42 (2009)
131. I. Han, M. Kim, H. Byun, T. Hwang, J. Kim, K. Hwang, T. Park, W. Jung, T Chun. GJ Jeong, YK Oh: Enhanced brain targeting efficiency of intranasally administered plasmid DNA: an alternative route for brain gene therapy. J Mol Med 85, 75-83 (2007) (Pubitemid 46020944)
132. I. Rakover, N Zabavnik. R Kopel, M Paz-Rozner, B Solomon: Antigen-specific therapy of EAE via intranasal delivery of filamentous phage displaying a myelin immunodominant epitope. J Neuroimmunol 225, 68-76 (2010)
133. L Danielyan. R Schafer, A vo. Ameln-Mayerhofer, M Buadze. J Geisler, T Klopfer. U Burkhardt, B Proksch. S Verleysdonk, M Ayturan. GH Buniatian, C. Gleiter, W. Frey, 2nd: Intranasal delivery of cells to the brain. Eur J Cell Biol 88, 315-324 (2009)
134. C. van Velthoven, A Kavelaars. F van Bel, CJ Heijnen: Nasal administration of stem cells: a promising novel route to treat neonatal ischemic brain damage. Pediatr Res 68, 419-422 (2010)
135. AL Rosenbloom: Obesity, Insulin Resistance, beta-Cell Autoimmunity, and the Changing Clinical Epidemiology of Childhood Diabetes. Diabetes Care 26, 2954-2956 (2003) (Pubitemid 37205576)
136. S Wild. G Roglic, A Green. R Sicree, H King: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047-1053 (2004) (Pubitemid 38579764)
137. L. Lipscombe, JE Hux: Trends in diabetes prevalence, incidence, and mortality in Ontario, Canada 1995-2005: a population-based study. Lancet. 369, 750-756 (2007) (Pubitemid 46321630)
138. K Nanto-Salonen. A Kupila, S Simell. H Siljander, T Salonsaari. A Hekkala, S Korhonen. R Erkkola, J. Sipila, L Haavisto. M Siltala, J Tuominen. J Hakalax, H Hyoty. J Ilonen, R Veijola. T Simell, M Knip, O Simell: Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 372, 1746-1755 (2008)
139. G. Biessels, F. De Leeuw, J Lindeboom. F Barkhof, P Scheltens: Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus. J Neurol Neurosurg Psychiatry 77, 304-307 (2006)
140. T de. Heijer, S. Vermeer, E. van Dijk, N. Prins, P. Koudstaal, A Hofman, MM Breteler: Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 46, 1604-1610 (2003) (Pubitemid 38005322)
141. B. Lobnig, O Kromeke. C Optenhostert-Porst, OT Wolf: Hippocampal volume and cognitive performance in long-standing Type 1 diabetic patients without macrovascular complications. Diabet Med 23, 32-39 (2006)
142. S. Manschot, A. Brands, G. van der, R. Kessels, A Algra. LJ Kappelle, GJ Biessels: Brain magnetic resonance imaging correlates of impaired cognition in patients with type 2 diabetes. Diabetes 55, 1106-1113 (2006) (Pubitemid 44100188)
143. T Matsuzaki. K Sasaki, Y Tanizaki. J Hata, K Fujimi. Y Matsui, A Sekita. SO Suzuki, S Kanba. Y Kiyohara, T Iwaki: Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology 75, 764-770
144. G. Biessels, I. Deary, CM Ryan: Cognition and diabetes: a lifespan perspective. Lancet Neurol 7, 184-190 (2008)
145. A Kupila. J Sipila, P Keskinen. T Simell, M Knip. K Pulkki, O Simell: Intranasally administered insulin intended for prevention of type 1 diabetes-a safety study in healthy adults. Diabetes Metab Res Rev 19, 415-420 (2003) (Pubitemid 37185383)
146. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 333, 1581-1587 (1995)
147. JL Frey: Recombinant tissue plasminogen activator (rtPA) for stroke. The perspective at 8 years. Neurologist 11, 123-133 (2005) (Pubitemid 40388435)
148. P. Gluckman, GR Ambler: Therapeutic use of insulin-like growth factor I: lessons from in vivo animal studies. Acta Paediatr Suppl 383, 134-136 (1992)
149. J Guan. C Williams, M Gunning. C Mallard, P Gluckman: The effects of IGF-1 treatment after hypoxicischemic brain injury in adult rats. J Cereb Blood Flow Metab 13, 609-616 (1993) (Pubitemid 23187504)
150. X. Liu, J. Fawcett, R. Thorne, T. De For, W. Frey, 2nd: Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J Neurol Sci 187, 91-97 (2001) (Pubitemid 32618661)
151. X. Liu, J. Fawcett, R. Thorne, WH Frey: Non-invasive intranasal insulin-like growth factor-I reduces infarct volume and improves neurologic function in rats following middle cerebral artery occlusion. Neuroscience Letters 308, 91-94 (2001) (Pubitemid 32703675)
152. X. Liu, J. Fawcett, L. Hanson, WH Frey: The window of opportunity for treatment of focal cerebral ischemic damage with noninvasive intranasal
153. S Lin. LW Fan, P. Rhodes, Z Cai: Intranasal administration of IGF-1 attenuates hypoxic-ischemic brain injury in neonatal rats. Exp Neurol 217, 361-370 (2009)
154. Y. Yu, Q. Xu, Q Zhang. WP Zhang, L. Zhang, EQ Wei: Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci Lett 387, 5-10 (2005) (Pubitemid 41138199)
155. M Digicaylioglu. G Garden, S Timberlake. L Fletcher, SA Lipton: Acute neuroprotective synergy of erythropoietin and insulin-like growth factor I. Proc Natl Acad Sci U S A 101, 9855-9860 (2004) (Pubitemid 38869326)
156. L Fletcher. S Kohli, S. Sprague, R. Scranton, S. Lipton, A Parra. DF Jimenez, M Digicaylioglu: Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke. Laboratory investigation. J Neurosurg 111, 164-170 (2009)
157. S. Alcala-Barraza, M. Lee, L. Hanson, A. McDonald, W. Frey, LK McLoon: Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. J Drug Target, (2009)
158. J. Yang, H. Liu, S. Cheng, Z. Wang, X Cheng. HX Yu, XF Liu: Direct transport of VEGF from the nasal cavity to brain. Neurosci Lett 449, 108-111 (2009)
159. J. Yang, H. Liu, Z. Wang, S. Cheng, X Cheng. GL Xu, XF Liu: The dose-effectiveness of intranasal VEGF in treatment of experimental stroke. Neurosci Lett 461, 212-216 (2009)
160. P Henrich-Noack. JH Prehn, J Krieglstein: TGF-beta 1 protects hippocampal neurons against degeneration caused by transient global ischemia. Dose-response relationship and potential neuroprotective mechanisms. Stroke 27, 1609-1614; discussion 1615 (1996)
161. M Ma. Y Ma, X Yi. R Guo, W Zhu. X Fan, G Xu. WH Frey, 2nd, X Liu: Intranasal delivery of transforming growth factor-beta1 in mice after stroke reduces infarct volume and increases neurogenesis in the subventricular zone. BMC Neurosci 9, 117 (2008)
162. Z. Wang, S. Cheng, M. Ma, Y. Ma, J. Yang, G. Xu, XF Liu: Intranasally delivered bFGF enhances neurogenesis in adult rats following cerebral ischemia. Neurosci Lett 446, 30-35 (2008)
163. K Jin. L Xie, J Childs. Y Sun, X. Mao, A Logvinova, DA Greenberg: Cerebral Neurogenesis Is Induced by Intranasal Administration of Growth Factors. Ann Neurol 53, 405-409 (2003) (Pubitemid 36258647)
164. M Guerra-Crespo. D Gleason, A Sistos. T Toosky, I Solaroglu. JH Zhang, P. Bryant, JH Fallon: Transforming growth factor-alpha induces neurogenesis and behavioral improvement in a chronic stroke model. Neuroscience 160, 470-483 (2009)
165. M Guerra-Crespo. A Sistos, D Gleason, JH Fallon: Intranasal administration of PEGylated transforming growth factor-alpha improves behavioral deficits in a chronic stroke model. J Stroke Cerebrovasc Dis 19, 3-9
166. S Cheng. M Ma, Y Ma. Z Wang, G Xu, X Liu: Combination therapy with intranasal NGF and electroacupuncture enhanced cell proliferation and survival in rats after stroke. Neurol Res 31, 753-758 (2009)
167. C Justicia. P Ramos-Cabrer, M Hoehn: MRI detection of secondary damage after stroke: chronic iron accumulation in the thalamus of the rat brain. Stroke 39, 1541-1547 (2008)
168. Y. Li, S. Ding, L Xiao. W Guo, Q Zhan: Desferoxamine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1 alpha and erythropoietin. Neurosci Bull 24, 89-95 (2008) (Pubitemid 351738284)
169. L. Hanson, A Roeytenberg. PM Martinez, V. Coppes, D. Sweet, R. Rao, D. Marti, J. Hoekman, R. Matthews, W. Frey, 2nd, SS Panter: Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J Pharmacol Exp Ther 330, 679-686 (2009)
170. B. Sun, F. Shen, Q. Wu, S. Chi, M. Yang, H Yuan. FM Xie, Y. Zhang, J Chen, F Zhang: Intranasal delivery of calcitonin gene-related peptide reduces cerebral vasospasm in rats. Front Biosci (Elite Ed) 2, 1502-1513 (2010)